Skip to main content

Advertisement

SpringerLink
Log in

Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study

  • Original Article
  • Published:
Updates in Surgery Aims and scope Submit manuscript

Abstract

Medical treatment has changed drastically in recent years, especially for advanced stages of non-small-cell lung cancer (NSCLC), for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. This single-center retrospective study aimed to analyze the outcome predictors, the surrogate outcomes, and the patient-reported outcomes after neoadjuvant immunotherapy for initially unresectable NSCLC. Patients affected by an initially unresectable NSCLC and identified between March 2014 and December 2021 who received immunotherapy alone or in combination with platinum-based chemotherapy and/or radiotherapy were collected. Overall survival (OS) and disease-free survival (DFS) were estimated according to the Kaplan–Meier method. Patient-reported outcomes were recorded using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life (QoL) Group questionnaire—Lung Cancer 29 Module to compare differences in symptoms and QoL at two different times, 30 days and 1 year after surgery. Surgical, pathological records, and patient-reported outcomes (at 30 days and 1 year after surgery) were reviewed. Complete pathological remission was achieved in 7 patients (36.8%) and major pathological remission in 3 patients (15.7%). The median overall survival in the study group is 19 months (range: 2–57.4). Of 19 patients, 16 (84.2%) are alive to date, of which 2 (10.5%) have a local recurrence. At 30 days from surgery, the main symptoms reported by EORTC Module were coughing, shortness of breath, the side effect of treatment, fear of progression, and surgery-related problems. Induction immunotherapy with or without chemotherapy can be considered for unresectable locally advanced NSCLC, and after the downstaging, the possibility of surgery could be re-evaluated in a multidisciplinary setting with high rates of R0 resection. In this selected and highly motivated group of patients, the QoL and symptoms after salvage surgeries are acceptable and even better than those reported in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

  1. Bertolaccini L, Mohamed S, Bardoni C, Lo Iacono G, Mazzella A, Guarize J, Spaggiari L (2022) The interdisciplinary management of lung cancer in the European community. J Clin Med. https://doi.org/10.3390/jcm11154326

    Article  PubMed  PubMed Central  Google Scholar 

  2. Pöttgen C, Eberhardt W, Stamatis G, Stuschke M (2017) Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC)—a cumulative meta-analysis of the randomized evidence. Oncotarget 8(25):41670–41678

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nakagawa K, Watanabe SI, Kunitoh H, Asamura H (2017) The lung cancer surgical study group of the japan clinical oncology group: past activities, current status and future direction. Jpn J Clin Oncol 47:194–199

    Article  PubMed  Google Scholar 

  4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Meyerson MSci 304(5676):1497–1500

    CAS  Google Scholar 

  5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963–1971

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y et al (2019) Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol 37:2235–2245

    Article  CAS  PubMed  Google Scholar 

  8. Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E et al (2019) Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 158:269–276

    Article  CAS  PubMed  Google Scholar 

  9. Chaft JE, Hellmann D, Velez MJ, Travis WD, Rusch VW (2017) Initial experience with lung cancer resection after treatments with T-cell checkpoint inhibitors. Ann Thorac Surg 104:e217–e218

    Article  PubMed  PubMed Central  Google Scholar 

  10. Passaglia F, Bertolaccini L, Del Re M et al (2019) Diagnosis and treatment of early and locally advanced non-small cell lung cancer: the 2019 AIOM (Italian association of medical oncology) clinical practice guidelines. Crit Rev Oncol Hematol. https://doi.org/10.1016/j.critrevonc.2019.102862

    Article  Google Scholar 

  11. Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS (2016) Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. Oncologist 21(6):684–691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gray JE, Villegas A, Daniel D et al (2020) Three-year overall survival with durvalumab after chemo-radiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 15:288–293

    Article  CAS  PubMed  Google Scholar 

  13. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G, Group, S (2019) STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 72:156–165. https://doi.org/10.1016/j.ijsu.2019.11.002

    Article  PubMed  Google Scholar 

  14. Travis WD, Dacic S, Wistuba I et al (2020) IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol 15:709–740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hellmann MD, Chaft JE, William WN Jr et al (2014) Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15:e42-50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, Arraras JI, Morag O, Pompili C, Ioannidis G, Georgiou M, Navarra C, Chie WC, Johnson CD, Himpel A, Schulz C, Bohrer T, Janssens A, Kulis D, Bottomley A, EORTC Quality of Life Group, EORTC Lung Cancer Group, and European Society of Thoracic Surgeons (2017) An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol 28(11):2874–2881. https://doi.org/10.1093/annonc/mdx453. (PubMed PMID: 28945875)

    Article  CAS  PubMed  Google Scholar 

  17. Team, R (2021) RStudio: integrated development environment for R. RStudio Inc, Boston

    Google Scholar 

  18. Team, RC (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

    Google Scholar 

  19. Nawashiro A, Tanaka F, Taira A, Shinohara S, Takenaka M, Kuroda K, Shimajiri S (2022) Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer. Surg Case Rep 8:17. https://doi.org/10.1186/s40792-022-01371-3

    Article  PubMed  PubMed Central  Google Scholar 

  20. Minegishi K, Tsubochi H, Ohno K, Komori K, Ozeki M, Endo S (2021) Salvage surgery post definitive chemo-radiotherapy and durvalumab for lung cancer. Ann Thorac Surg 112:e53–e55

    Article  PubMed  Google Scholar 

  21. Jiang L, Huang J, Li C, Shen Y, Zhang Y, Lu S, Luo Q (2020) Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report. Transl Lung Cancer Res 9(3):803–806. https://doi.org/10.21037/tlcr-20-517

    Article  PubMed  PubMed Central  Google Scholar 

  22. Li L, Chen T, Lai H, Zhang A, Zhao X, Wu J, Hong H, Wu L, Lin S, Wang K, Zhang H, Fang C (2022) Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy. Medicine 101:23(e29336)

    PubMed  Google Scholar 

  23. Ma D, Xu Y, Qin Y, Li S, Li J, Jiang Y, Wang M, Xu Y, Zhao J, Chen M, Cheng W, Hu K, Liu H (2022) Neoadjuvant immunotherapy followed by surgery with curative intent in 35 patients with advanced NSCLC: the retrospective experiences of a multidisciplinary team. Ann Transl Med 10(10):609. https://doi.org/10.21037/atm-22-2271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Deng H, Liu J, Cai X, Chen J, Rocco G, Petersen RH, Brunelli A, Ng CSH, D’Amico TA, Liang W, He J (2022) Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer. Ann Surg. https://doi.org/10.1097/SLA.0000000000005233

    Article  PubMed  Google Scholar 

  25. Galetta D, De Marinis F, Spaggiari L (2022) Rescue surgery after immunotherapy/tyrosine kinase inhibitors for initially unresectable lung cancer. Cancers 14:2661. https://doi.org/10.3390/cancers14112661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ueno T, Yamashita M, Yamashita N, Uomoto M, Kawamata O, Sano Y, Inokawa H, Hirayama S, Okazaki M, Toyooka S (2022) Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg 70(9):812–817. https://doi.org/10.1007/s11748-022-01798-3. (Epub 2022 March 19th PMID: 35304712)

    Article  PubMed  Google Scholar 

  27. Travis WD, Dacic S, Wistuba I et al (2020) IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol 15:709–740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, Provencio M, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, De Ruysscher D, Ramirez RA, Dempke WCM, Camidge DR, Guibert N, Califano R, Wang Q, Ren S, Zhou C, He J (2020) Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 9(6):2696–2715. https://doi.org/10.21037/tlcr-2020-63. (PMID: 33489828; PMCID: PMC7815365)

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ettinger DS, Wood DE, Aggarwal C et al (2019) NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 17:1464–72

    Article  PubMed  Google Scholar 

  30. Kar P, Sudheshna KD, Padmaja D, Pathy A, Gopinath R (2019) Chronic pain following thoracotomy for lung surgeries: it’s risk factors, prevalence, and impact on quality of life—a retrospective study. Indian J Anaesth 63:368–374

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pompili C, Trevis J, Patella M, Brunelli A, Libretti L, Novoa N et al (2021) European society of thoracic surgeons electronic quality of life application after lung resection: field testing in a clinical setting. Interact CardioVasc Thorac Surg 32:911–920

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds.

Author information

Author notes

  1. Shehab Mohamed and Luca Bertolaccini have contributed equally to this manuscript.

Authors and Affiliations

  1. Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy

    Shehab Mohamed, Luca Bertolaccini, Monica Casiraghi, Francesco Petrella, Domenico Galetta & Lorenzo Spaggiari

  2. Unit of Interventional Pneumology, IEO, European Institute of Oncology IRCCS, Milan, Italy

    Monica Casiraghi, Francesco Petrella, Domenico Galetta & Lorenzo Spaggiari

  3. Department of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy

    Juliana Guarize

  4. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

    Filippo de Marinis

  5. Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy

    Luca Bertolaccini

Authors
  1. Shehab Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Bertolaccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monica Casiraghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Petrella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenico Galetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juliana Guarize
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Filippo de Marinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lorenzo Spaggiari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Bertolaccini.

Ethics declarations

Conflict of interest

None.

Informed consent

Informed consent was obtained from all patients who agreed to participate in this study.

Ethical approval and Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohamed, S., Bertolaccini, L., Casiraghi, M. et al. Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study. Updates Surg 75, 2355–2363 (2023). https://doi.org/10.1007/s13304-023-01644-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-023-01644-y

Keywords

Search

Navigation